Skip to main content
Clinical Trials/NCT03634566
NCT03634566
Completed
Phase 1

Effect of N_Acetylcysteine on Liver Functions in Donors in Living Donor Liver Transplantation

Ain Shams University1 site in 1 country50 target enrollmentApril 1, 2018

Overview

Phase
Phase 1
Intervention
N-Acetylecysteine
Conditions
Liver Transplant; Complications
Sponsor
Ain Shams University
Enrollment
50
Locations
1
Primary Endpoint
Serum lactate
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

our practice for the past 10 years we have noticed a transitional impairment of liver function (elevated liver enzymes, total and direct bilirubin, and elevated serum lactate levels) following donors' liver resection. Several drugs have been investigation on liver regeneration , proven benefit of N-Acetylcysteine (NAC) on rats with steatohpatitis

Registry
clinicaltrials.gov
Start Date
April 1, 2018
End Date
April 1, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mona Ammar

Lecturer of anesthesia,intensive care and pain management

Ain Shams University

Eligibility Criteria

Inclusion Criteria

  • ASA I or II donors
  • healthy adult

Exclusion Criteria

  • kidney, liver disease
  • any contraindications for organ donation

Arms & Interventions

NAC group

Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days

Intervention: N-Acetylecysteine

Control group

Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.

Intervention: Placebo

Outcomes

Primary Outcomes

Serum lactate

Time Frame: 24 hours postoperative

Study Sites (1)

Loading locations...

Similar Trials